3 Out of 5 Liver Cancer Cases Are Preventable, Study Finds
The research found that prevention could be accomplished by addressing the disease's major causes: hepatitis B, hepatitis C, alcohol-associated liver disease and liver disease linked to metabolic risk factors like obesity.
With nearly 900,000 new cases globally each year, liver cancer is the sixth most common cancer and the third leading cause of death from cancer. If cases continue to rise at the current rate, the number of new annual diagnoses will almost double, rising to 1.5 million globally in 2050, the study predicted. The researchers estimated that liver disease from alcohol use and metabolic dysfunction together would account for nearly one-third of new liver cancer cases by then.
The findings align with what liver specialists have seen in their clinics for years.
'Liver cancer is common, it causes immense suffering and death, and the saddest part for me as a physician is that most of the cases are preventable,' said Dr. Brian P. Lee, an associate professor of medicine at the Keck School of Medicine at the University of Southern California, who was not involved in the study.
Improved screening, vaccination and treatment in recent years have helped stem viral hepatitis, especially in the United States. But the threat of liver cancer from heavy alcohol use and metabolic dysfunction-associated steatotic liver disease, or MASLD, formerly known as nonalcoholic fatty liver disease, 'has been underrecognized and underestimated,' said Dr. Ahmed Kaseb, a professor of gastrointestinal medical oncology at the University of Texas MD Anderson Cancer Center, who was not associated with the study.
A 'Highway' to Liver Cancer
A vast majority of liver cancers arise in people with cirrhosis, said Dr. Hashem El-Serag, the chair of the department of medicine at Baylor College of Medicine in Texas and one of the authors of the new study. Cirrhosis, or advanced and largely irreversible scarring of the liver, damages healthy tissue and prevents the organ from working normally.
Want all of The Times? Subscribe.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 hours ago
- Yahoo
Could Your Birth Control Method Be Affecting Your Performance In The Gym? Here's What Experts Say
"Hearst Magazines and Yahoo may earn commission or revenue on some items through these links." Thanks to TikToks, sketchy health blogs, and Thanksgiving soapboxes courtesy of your toxic aunt, the rumor that birth control affects your ability to perform athletically has been spread far and wide for way too long. We get why it's confusing. Hormonal birth control methods such as contraceptive pills alter your hormones, which can affect…well, everything else, like your workouts. But, science hasn't exactly found that to be true. Plus, there are several kinds of birth control methods; some are more studied than others. We have some limited information on how oral contraceptive pills (OCPs) affect athletic performance in females. Other forms, including intrauterine devices (IUDs) with and without hormones, as well as implants, work differently and are even less studied. We consulted the experts to find out what we know, and what we don't, about how your birth control may affect your workouts. Meet the Experts: Jessica Shepherd, MD, is a board-certified ob-gyn, author of Generation M: Living Well in Perimenopause and Menopause, and Women's Health advisory board member. Bailey McLagan is a PhD candidate in exercise physiology at the University of Southern California, who specializes in women's performance research, including how birth control affects workouts. It's difficult to generalize these medications' effects since there are a bunch of different types, and they affect women differently. The most commonly used is oral contraceptives. These medications include synthetic hormones and generally work by "sending a signal to our brain to tell our body not to release an egg,' says Bailey McLagan, MS, a PhD candidate in exercise physiology at the University of Southern California, who studies the role of female hormones in exercise and recovery. 'The goal is to prevent ovulation, thus preventing the possibility of getting pregnant.' They can cause a handful of side effects that may indirectly affect performance, such as mood changes, spotting, cramping, nausea, or headaches. Even though these side effects are possible, it's important to note that not everyone will experience them, McLagan notes. Beyond side effects, 'it's not clear what, if any, effect OCPs have on training,' McLagan says. 'This is because there are so many kinds that are often not recorded in research and because studies don't often differentiate between OCP users and non-users.' One 2022 study, for example, looked at hormonal oral birth control effects on strength training outcomes, including muscle thickness, muscle fiber size, and composition over a 12-week period. They found that factors were similar between women who did and did not use oral contraceptives, says Jessica Shepherd, MD, board-certified ob-gyn and Women's Health advisory board member. START YOUR STRENGTH TRANSFORMATION Another study looked at exercise performance factors such as workload, exhaustion, time to completion, mean peak outputs, rate of production, and maximal oxygen intake between oral contraception users and non-users. The study found a trivial reduction in performance factors in those using oral contraception. 'It's important to remember that performance is impacted by a lot of things, so a trivial reduction doesn't signify an advantage in one over the other,' McLagan says. Some studies have looked at the impact of hormonal birth control on VO2 max—a measure of how much oxygen you use during training, Dr. Shepherd says. When VO2 max is high, it means that your body is more efficient at delivering oxygen to the muscles, Dr. Shepherd says. One study found the use of oral contraceptives might lower VO2 max. As mentioned, oral contraceptives aren't the only form of birth control. Dr. Shepherd says hormonal IUDs have shown some positive results. In one study, it was found to be the best-tolerated contraceptive for female endurance athletes. It also had the highest percentage of users who perceived positive training and competition impacts. 'Overall, there should be better research that looks at a prospective, randomized design to assess the effects of all types of hormonal contraceptives on athletic performance in females,' Dr. Shepherd says. What we do know: Much more research needs to be done to determine the effects of different birth control methods on training performance. Ultimately, how your experience on how birth control affects your workouts will differ from others. Therefore, you might have to go through some level of trial and error to determine what works for you. If you're on a new form of birth control, your doctor might tell you to stay on it for more than a month to see if potential symptoms subside or not. Ultimately, you shouldn't have to choose between being on birth control and getting the workout results you want. There are a ton of reasons to stay on birth control beyond pregnancy prevention—and there are tons of options to choose from. So don't be afraid to advocate for yourself to find the one that gives you the best results in all aspects of your life. 'If a certain form of OCP is making you feel uncomfortable, it may be that you need a different formulation of hormones, a lower dose, or switch to a different birth control method altogether,' McLagan says. Keep an open line of communication with your doctor, and adjust as necessary until you find a path that works for you. You Might Also Like Jennifer Garner Swears By This Retinol Eye Cream These New Kicks Will Help You Smash Your Cross-Training Goals
Boston Globe
6 hours ago
- Boston Globe
Three out of five liver cancer cases are preventable, study finds
Advertisement The findings align with what liver specialists have seen in their clinics for years. 'Liver cancer is common, it causes immense suffering and death, and the saddest part for me as a physician is that most of the cases are preventable,' said Dr. Brian P. Lee, an associate professor of medicine at the Keck School of Medicine at the University of Southern California, who was not involved in the study. Improved screening, vaccination and treatment in recent years have helped stem viral hepatitis, especially in the United States. But the threat of liver cancer from heavy alcohol use and metabolic dysfunction-associated steatotic liver disease, or MASLD, formerly known as nonalcoholic fatty liver disease, 'has been underrecognized and underestimated,' said Dr. Ahmed Kaseb, a professor of gastrointestinal medical oncology at the University of Texas MD Anderson Cancer Center, who was not associated with the study. Advertisement A 'highway' to liver cancer A vast majority of liver cancers arise in people with cirrhosis, said Dr. Hashem El-Serag, the chair of the department of medicine at Baylor College of Medicine in Texas and one of the authors of the new study. Cirrhosis, or advanced and largely irreversible scarring of the liver, damages healthy tissue and prevents the organ from working normally. The hepatitis B and C viruses cause inflammation that, if left untreated, can scar and damage the liver, potentially leading to cirrhosis. And both alcohol and metabolic dysfunction lead to abnormal deposits of fat in the liver, which can also result in inflammation. Related : Lee said the accumulation of fat and inflammation acted as a 'highway' to liver scarring, which in turn can injure DNA and lead to cancer. 'There could be multiple ramps to get onto that highway,' he said. Why disease may go undetected The new paper found that the share of liver cancers resulting from hepatitis B and hepatitis C is expected to drop to 63% in 2050, from 68% in 2022. But the burden of liver cancers resulting from alcohol and MASLD is expected to grow. An estimated 4 in 10 adults worldwide have MASLD, a condition in which fat builds up in the liver. Risk factors include obesity and Type 2 diabetes. A subset of patients with MASLD will go on to develop an advanced form called metabolic dysfunction-associated steatohepatitis, or MASH, which has been described as a silent killer because it can progress to cirrhosis and liver cancer without being noticed. Current guidance recommends monitoring for liver cancers in patients who have a history of viral hepatitis or established cirrhosis. Patients with MASH typically don't meet that criteria, Kaseb said, but they could have liver scarring without symptoms, and nobody would know. Related : Advertisement That's why screening for liver disease needs to begin at the primary care level, where cases can easily go undetected, said Dr. Mary Rinella, a hepatologist at University of Chicago Medicine and the lead author of guidelines for the management of MASLD. She recommended that doctors use a metric called the Fib-4, which uses routine blood test results to estimate the amount of liver scarring, to screen high-risk patients. These include people who have Type 2 diabetes or obesity with at least one other metabolic risk factor, such as high cholesterol. MASLD is reversible with lifestyle changes, including a healthy diet and increased exercise, and weight-loss drugs have recently been shown to be effective at reversing scarring as well. 'If you stop the reason or the impetus for scarring and injury in the liver, then you're going to have less impetus for the development of cancer,' Rinella said. Alcohol compounds the problem Alcohol-related liver disease is also on the rise. In research published this month, Lee and his colleagues showed that the risk of alcohol-related liver disease among heavy drinkers (at least 10 drinks per week for women and 15 for men) in the United States more than doubled between 1999 and 2020, despite similar alcohol use over that period. That suggests that heavy drinkers today may be more sensitive to the effects of alcohol on the liver than those in the past, Lee said. This may be because the population of heavy drinkers is changing. The researchers found that women, who are more prone than men to develop fat and damage in the liver from alcohol, now make up a greater share of heavy drinkers than they did 20 years ago. So do people with metabolic syndrome, a cluster of metabolic disorders that together raise the risk of diabetes, heart disease and stroke — and compound the damage done by alcohol to the liver. Related : Advertisement Drinking heavily and having a metabolic condition such as obesity can independently damage the liver, but patients who fall in both categories are at an especially high risk. These trends are likely to continue. 'Alcohol use is increasing,' Rinella said. 'Obesity and diabetes are increasing.' 'I expect that we're going to continue to see a high burden of liver disease,' she added. This article originally appeared in .
Yahoo
10 hours ago
- Yahoo
Liver cancer cases could double by 2050. A new study says 60% are preventable
Liver cancer is on the rise, but experts say it doesn't have to be this way. A new analysis published by an expert panel on liver cancer has shown that three out of five liver cancer cases worldwide are linked to preventable risk factors. These include viral hepatitis, alcohol consumption, and an increasingly common but often overlooked threat: obesity-related liver disease. Without urgent intervention, the number of liver cancer cases is expected to nearly double from 870,000 in 2022 to 1.52 million by 2050, with annual deaths rising from 760,000 to 1.37 million. But experts argue that millions of lives can be saved with targeted prevention and policy reforms. Liver cancer "is one of the most challenging cancers to treat, with five-year survival rates ranging from approximately 5 per cent to 30 per cent,' said Jian Zhou, a professor at Fudan University in China and chair of the Lancet commission. 'We risk seeing close to a doubling of cases and deaths from liver cancer over the next quarter of a century without urgent action to reverse this trend,' Zhou said in a statement. A shifting landscape of risk Traditionally associated with hepatitis infections and heavy alcohol use, liver cancer is now being increasingly driven by metabolic dysfunction-associated steatotic liver disease (MASLD), once commonly known as non-alcoholic fatty liver disease. MASLD is one of the most common liver conditions in Europe, affecting up to 25 per cent of the adult population, Beatrice Credi of the European Liver Patients' Association (ELPA) told Euronews Health. 'It is crucial to stress that while these risk factors are prevalent, they are often preventable or manageable with appropriate intervention,' she added, emphasising the importance of education as well as robust public health campaigns. This long-term liver condition is linked to obesity and poor metabolic health. Its more severe form, known as MASH (metabolic dysfunction-associated steatohepatitis), is the fastest-growing cause of liver cancer globally. Related Global obesity rates are surging as people gain weight younger and faster than in the past The Lancet commission projects that liver cancers linked to MASH will increase by 35 per cent, rising from 8 per cent of cases in 2022 to 11 per cent by 2050. Liver cancers related to alcohol are also expected to rise modestly. Meanwhile, cases caused by hepatitis B and C are predicted to decline slightly thanks to vaccination and improved treatment efforts. Numbers are particularly concerning in high-income countries, where obesity rates are soaring. In the United States, MASLD is expected to affect more than half of all adults by 2040, dramatically increasing liver cancer risk. According to Dr Hashem El-Serag, a professor at Baylor College of Medicine, the profile of the disease is evolving. 'Liver cancer was once thought to occur mainly in patients with viral hepatitis or alcohol-related liver disease,' he said. But with obesity on the rise, it is becoming an increasingly prominent risk factor, largely due to growing cases of excess liver fat. The prevention opportunity Despite the grim projections, the Lancet commission offers a glimmer of hope: the potential of prevention. If new liver cancer cases are reduced by 2 per cent to 5 per cent each year, it could prevent up to 17 million new cases and save as many as 15 million lives by 2050. Related EU can dodge millions of cancers by hitting tobacco, alcohol reduction targets, study claims Achieving that would require a multi-pronged global effort, including expanding hepatitis B vaccination and universal adult HBV screening, as well as tackling obesity and alcohol misuse through taxes, warning labels, and better food and beverage policies. The Lancet commission also suggests integrating liver screening into routine care for people with obesity, diabetes, and heart disease and investing in public education and early detection tools. 'As three in five cases of liver cancer are linked to preventable risk factors ... there is a huge opportunity for countries to target these risk factors, prevent cases of liver cancer, and save lives,' said Stephen Chan, lead author of the study and a professor ar the Chinese University of Hong Kong. A global call to action In Europe, recent policy shifts have increasingly emphasised prevention and early detection. The European Union's Beating Cancer Plan aims to achieve 95 per cent coverage for childhood hepatitis B vaccination and screening of pregnant women by 2030. It also encourages healthier lifestyle choices and aims to reduce exposure to known risk factors such as alcohol, tobacco, obesity, and diabetes. Related Weight-loss drugs like Wegovy could help serious liver condition that has no cure-all treatment A policy recommendation issued by the European Commission in January called for expanded uptake of preventive vaccines (specifically HPV and hepatitis B) and improved monitoring of vaccine coverage rates. But in the fight against liver cancer, the EU must also confront a less visible but equally powerful force: the commercial determinants of health, said ELPA's Beatrice Credi. 'Industries that profit from the sale of alcohol, unhealthy foods, and tobacco play a significant role in driving some of the liver cancer risk factors. Our policymakers must prioritise public health,' she told Euronews Health. She noted, however, that policies aimed at regulating these commercial influences remain weak or inconsistently enforced across the EU, with the only exception of taxes on sugar-sweetened beverages. Related Millions in Europe unknowingly living with hepatitis, health authorities warn Prevention alone is not enough. As more people are now living with liver cancer than ever before, the Lancet commission stressed the urgent need for improved care, earlier diagnosis, and better support for patients—especially in regions such as Africa and Asia, where the disease burden is highest and health care resources are limited. But Valérie Paradis, a professor at Beaujon Hospital in France, suggested effective prevention could also help ease that burden. 'Compared with other cancers, liver cancer is very hard to treat but has more distinct risk factors, which help define specific prevention strategies,' Paradis said.
